Global Stroke Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Stroke Market Analysis

The global stroke market is witnessing significant growth due to increasing awareness of stroke prevention and advancements in treatment options. Stroke, a leading cause of disability and mortality worldwide, has prompted healthcare systems to focus on early diagnosis, effective treatment, and rehabilitation. Recent developments in the market include the introduction of innovative therapies, such as thrombectomy devices and advanced imaging techniques, which enable quicker and more accurate diagnosis and intervention. For instance, the FDA's approval of the Penumbra 5 MAX aspiration system has enhanced the efficacy of mechanical thrombectomy procedures for ischemic stroke patients. In addition, the integration of telemedicine has revolutionized patient management, allowing for remote monitoring and consultation, which is particularly beneficial in rural areas where access to specialized care may be limited. Moreover, initiatives aimed at educating the public about stroke symptoms and risk factors are also contributing to early detection and treatment, further driving market growth.

Stroke Market Size

The global stroke market size was valued at USD 32.57 billion in 2023 and is projected to reach USD 58.09 billion by 2031, with a CAGR of  7.50% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Stroke Market Trends

“Rising Adoption of Telemedicine for Stroke Care”

Le marché mondial des accidents vasculaires cérébraux connaît une croissance significative en raison de la sensibilisation croissante à la prévention des accidents vasculaires cérébraux et des progrès dans les options de traitement. Une tendance importante sur le marché des accidents vasculaires cérébraux est l'adoption croissante de la télémédecine pour les soins des accidents vasculaires cérébraux, ce qui améliore le diagnostic et le traitement en temps opportun. La télémédecine permet aux prestataires de soins de santé de mener des consultations à distance, ce qui permet d'évaluer rapidement les patients présentant des symptômes d'accident vasculaire cérébral. Cette approche s'est avérée cruciale, en particulier dans les zones rurales ou mal desservies où l'accès aux soins spécialisés contre les accidents vasculaires cérébraux peut être limité. Par exemple, le programme TeleStroke mis en œuvre par divers établissements de santé permet aux neurologues d'évaluer les patients par vidéoconférence, garantissant que les décisions en matière de soins intensifs peuvent être prises dans l'« heure d'or » cruciale qui suit le début d'un accident vasculaire cérébral. Cette intervention rapide est essentielle pour administrer un traitement thrombolytique, qui peut améliorer considérablement les résultats des patients. À mesure que la technologie continue d'évoluer, l'intégration de la télémédecine dans la gestion des accidents vasculaires cérébraux rationalise les processus de traitement et améliore l'engagement et l'éducation des patients, contribuant ainsi à de meilleurs taux de récupération et à une réduction des coûts des soins de santé sur le marché des accidents vasculaires cérébraux.

Portée du rapport et segmentation du marché des accidents vasculaires cérébraux       

Définition du marché des accidents vasculaires cérébraux

Un accident vasculaire cérébral (AVC), également appelé accident vasculaire cérébral (AVC), survient lorsque l'apport sanguin à une partie du cerveau est interrompu ou réduit, empêchant le tissu cérébral de recevoir de l'oxygène et des nutriments. Cette interruption peut être causée soit par un blocage des vaisseaux sanguins (AVC ischémique), soit par la rupture d'un vaisseau sanguin (AVC hémorragique). Le manque de flux sanguin peut entraîner la mort des cellules cérébrales en quelques minutes, ce qui entraîne différents degrés d'invalidité, selon la région cérébrale touchée et la durée de l'interruption.

Dynamique du marché des accidents vasculaires cérébraux

Conducteurs

• Augmentation de l'incidence des accidents vasculaires cérébraux

L’incidence croissante des accidents vasculaires cérébraux (AVC) est un problème de santé mondial urgent. Selon les statistiques de l’Organisation mondiale de la santé (OMS), environ 15 millions de personnes dans le monde en sont victimes chaque année. Cette augmentation peut être largement attribuée au vieillissement de la population, car le risque d’AVC augmente avec l’âge, en particulier chez les personnes de plus de 65 ans. En outre, les changements de mode de vie, notamment la sédentarité, une mauvaise alimentation et le tabagisme , ont entraîné une augmentation des facteurs de risque tels que l’hypertension, le diabète et l’obésité. En conséquence, le nombre croissant de cas d’AVC stimule considérablement la demande de traitements efficaces, de thérapies de réadaptation et d’outils de diagnostic avancés pour améliorer les résultats des patients et réduire le fardeau global de cette maladie débilitante, ce qui stimule la croissance du marché.

• Augmentation de la prévalence de l'hypertension et des maladies coronariennes

L'hypertension , souvent appelée hypertension artérielle, est une maladie caractérisée par une force accrue exercée par le sang contre les parois des artères. La maladie coronarienne (MC), également connue sous le nom de maladie des artères coronaires, se développe à partir de l'accumulation progressive de dépôts graisseux (athérosclérose) dans les artères coronaires, qui fournissent l'oxygène et les nutriments essentiels au muscle cardiaque. Il existe un lien étroit entre l'accident vasculaire cérébral et la prévalence croissante de l'hypertension et de la MC, car ils partagent des facteurs de risque et des mécanismes physiologiques sous-jacents communs. Plus précisément, l'hypertension artérielle augmente considérablement le risque d'accident vasculaire cérébral en endommageant les vaisseaux sanguins et en augmentant la probabilité de formation de caillots sanguins. L'hypertension chronique peut entraîner l'athérosclérose, entraînant le rétrécissement des vaisseaux sanguins et une réduction du flux sanguin vers le cerveau, ce qui augmente à son tour le risque d'accident vasculaire cérébral ischémique (causé par des blocages) et d'accident vasculaire cérébral hémorragique (causé par des saignements). De plus, une pression artérielle élevée peut compromettre l'intégrité des vaisseaux sanguins du cerveau, les rendant plus susceptibles de se rompre ou de se bloquer, augmentant ainsi encore le risque d'accident vasculaire cérébral. À mesure que la prévalence de l’hypertension et des maladies coronariennes augmente, la demande d’options efficaces de prévention et de traitement des accidents vasculaires cérébraux continuera de croître, stimulant le marché des outils de diagnostic et des interventions thérapeutiques innovants.

Opportunités

• Développement croissant de nouvelles thérapies

Le développement de nouvelles thérapies représente une opportunité de marché importante dans le domaine du traitement des accidents vasculaires cérébraux, car la R&D continue de progresser dans le domaine des produits pharmaceutiques. Les principaux domaines d’intérêt comprennent les agents neuroprotecteurs qui visent à protéger les cellules cérébrales pendant et après un accident vasculaire cérébral, les thérapies à base de cellules souches qui favorisent la régénération des tissus cérébraux et les médicaments innovants anticoagulants tels que les activateurs tissulaires du plasminogène (tPA) de nouvelle génération qui fonctionnent plus efficacement dans une fenêtre de traitement plus large. Par exemple, l’avancement des thérapies à base de cellules souches, telles que MultiStem développées par Athersys, s’est révélé prometteur pour favoriser la récupération neurologique en réduisant l’inflammation et en protégeant les neurones endommagés, en particulier chez les patients victimes d’un accident vasculaire cérébral ischémique. Ces nouvelles approches répondent à des besoins médicaux non satisfaits et ouvrent de nouvelles voies aux sociétés pharmaceutiques pour conquérir des parts de marché, d’autant plus que ces thérapies passent des essais cliniques à la disponibilité commerciale. Ce pipeline croissant de traitements innovants devrait élargir considérablement le marché du traitement des accidents vasculaires cérébraux, car la demande d’options plus efficaces et moins invasives augmente à l’échelle mondiale.

• Des progrès technologiques croissants

Advancements in technology present substantial opportunities for companies in the stroke market to improve treatment and management through the development of innovative medical devices and tools. For instance, thrombectomy devices, which are designed to remove blood clots from the brain, have revolutionized acute stroke care, enabling faster and more effective interventions that can dramatically reduce the risk of long-term disability. In addition, AI-powered diagnostic tools are emerging as crucial assets in stroke detection, providing rapid and accurate analysis of imaging data, which can facilitate timely decision-making. Companies such as Medtronic and Penumbra are leading the way with their advanced thrombectomy devices that have significantly improved patient outcomes. The integration of Such technologies enhances clinical efficacy and positions companies to capture a larger share of the growing stroke treatment market, making this technological advancement a key market opportunity for innovation and competitive advantage.

Restraints/Challenges

• Managing Stroke in Patients with Multiple Chronic Conditions

Managing stroke in patients with multiple chronic conditions poses significant challenges, as these concurrent health issues can complicate both treatment and recovery. One major complication arises from polypharmacy and medication interactions, where patients with multiple chronic conditions often require numerous medications. This situation increases the risk of drug interactions and adverse effects, making medication management particularly complex in stroke care. For instance, the use of anticoagulants or antiplatelet medications requires careful consideration to balance the risks of bleeding and clotting. As the prevalence of stroke patients with multiple chronic conditions rises, the complexities associated with polypharmacy present a notable market challenge, highlighting the need for innovative solutions to ensure safe and effective medication management.

• Significant Expenses Related to Stroke Treatment

The substantial costs associated with stroke treatment represent a significant concern within the healthcare landscape, affecting both patients and healthcare systems. The initial phase of stroke care entails emergency medical services, including ambulance transport, emergency room assessments, and diagnostic imaging such as CT scans and MRIs. The urgent nature and complexity of these services contribute to escalating expenses. As a result, the high financial burden of stroke treatment poses a considerable market challenge, hampering the overall development of the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Stroke Market Scope

The market is segmented on the basis of type, treatment, diagnosis, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Ischemic Stroke
• Transient Ischemic Attack (TIA)
• Hemorrhage Stroke

Treatment

• Medication
• Surgery
• Other Therapy

Diagnosis

• Imaging Test
• Blood Test
• Echocardiogram
• Lumbar Puncture
• Other

Gender

• Female
• Male

End User

• Hospitals & Clinics
• Specialty Clinics
• Ambulatory Surgical Centers
• Homecare
• Laboratories
• Others

Distribution Channel

• Direct
• Retail
• Online

Stroke Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the stroke market, driven by its strong presence of major industry players and its status as the largest consumer market with a high GDP. The region benefits from substantial investments in healthcare innovation and advanced medical technologies. The U.S., in particular, is set to dominate the North American market due to its continuous advancements in stroke-related products and cutting-edge treatment options, further boosting the market's growth potential.

Germany is expected to lead the European market, primarily due to the strong presence of key industry players and its well-established healthcare infrastructure. This strategic position allows Germany to drive innovation and growth in the region, further solidifying its market dominance.

China is anticipated to dominate the Asia-Pacific region, driven by the rising incidence of stroke and a growing demand from emerging markets. In addition, China's ongoing healthcare expansion and investments in medical advancements further strengthen its position in the regional market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Stroke Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Stroke Market Leaders Operating in the Market Are:

• Bayer AG (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Boehringer Ingelheim International GmbH (Germany)
• Sanofi (France)
• Bristol-Myers Squibb Company (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Medtronic (Ireland)
• Teva Pharmaceuticals USA, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• AstraZeneca (U.K.)
• Viatris Inc. (U.S.)
• Lupin (India)
• Abbott (U.S.)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• Penumbra, Inc. (U.S.)
• Oxford Laboratories Pvt. Ltd. (India)
• Sandoz Group AG (Switzerland)
• GLENMARK PHARMACEUTICALS LTD. (India)
• Fresenius SE & Co. KGaA (Germany)
• Amneal Pharmaceuticals LLC (U.S.)

Latest Developments in Stroke Market

• In October 2024, Siemens Healthineers announced its collaboration with over 20 industry and public partners, including seven prominent stroke hospitals, to enhance stroke management for patients throughout Europe. The five-year 'UMBRELLA' project, with a total budget of USD 29.30 million, is being funded in part by the Innovative Health Initiative (IHI), a public-private partnership aimed at health research and innovation between the European Union and the life sciences sector in Europe, as well as contributions from industry partners involved in the consortium
• In September 2024, Michigan-based medical device leader Stryker has finalized its acquisition of the Nico Corporation to enhance its neurotechnology and stroke care portfolio. This acquisition includes systems specifically designed for managing surgeries to treat intracerebral hemorrhages (ICH), known as BrainPath and Myriad. By integrating Nico's innovative technologies, Stryker aims to strengthen its offerings in the neurotechnology sector and improve treatment options for patients suffering from stroke-related conditions
• In August 2024, Christian Medical College (CMC) Vellore and IIT Madras unveiled a portable robotic device called PLUTO (Plug-and-Train Robot for Hand Neurorehabilitation) aimed at assisting stroke survivors in their recovery through hand movement therapy. This innovative device is crafted to be both affordable and user-friendly, ensuring accessibility for use in diverse environments such as hospitals, small clinics, community centers, and even at home
• In February 2024, Basking Biosciences, a clinical-stage biopharmaceutical company focused on developing an innovative acute thrombolytic therapy for stroke treatment, announced the completion of a USD 55 million financing round. The round was led by new investor ARCH Venture Partners, with contributions from other new investors including Insight Partners, Platanus, Solas BioVentures, and RTW Investments, alongside existing investors Longview Ventures, Rev1 Ventures, and The Ohio State University
• In May 2022, researchers at Osaka Metropolitan University began exploring robotic therapy as a promising treatment for stroke recovery during its chronic stage. If widely adopted, robotic therapy could enhance stroke patient care by offering a cost-effective solution with minimal need for direct supervision from therapeutic staff
• In April 2022, the U.S. National Institutes of Health (NIH) provided USD 1.8 million in funding for a project aimed at developing artificially grown, simplified mini-organs. These brain-like miniature organs are intended to produce particles that could be harvested for creating new medications targeting brain cells damaged by stroke

SKU-60379